Home > Healthcare > Pharmaceuticals > Vaccines > Influenza Vaccines Market

Influenza Vaccines Market Share

Report ID: GMI8037
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Influenza Vaccines Market Share

The influenza vaccines industry is characterized by the active participation of key pharmaceutical companies and biotech firms striving to address the public health challenges posed by seasonal and pandemic influenza. Leading players such as Sanofi, GlaxoSmithKline (GSK), CSL Limited have established themselves as major contributors to the market, offering a range of trivalent and quadrivalent influenza vaccines. The market continues to evolve, the competitive landscape is likely to be shaped by ongoing advancements, regulatory considerations, and responses to emerging infectious threats.

Influenza Vaccines Market Companies

Key leaders operating in the influenza vaccines industry are as mentioned below:

AstraZeneca plc
CSL Limited
Emergent Biosolutions
Gamma Vaccines Pty Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Sanofi SA
Sinovac Biotech Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The influenza vaccines market size was worth USD 7.1 billion in 2023 and is anticipated to be USD 13 billion by 2032, owing to the increasing prevalence of influenza.

The egg-based segment is anticipated to reach USD 10.8 billion by 2032, as these vaccines have been a longstanding and well-established method allowing for large-scale vaccine manufacturing.

North America influenza vaccines market is anticipated to grow at CAGR 6.5% through 2032, attributed to well-established healthcare infrastructure with numerous hospitals, clinics, and pharmacies.

AstraZeneca plc., Viatris Inc., CSL Limited, Sinovac Biotech Ltd., Emergent Biosolutions, Sanofi SA, Gamma Vaccines Pty Ltd., Novartis AG, GlaxoSmithKline plc and Merck & Co., Inc.